{
  "doc_id": "bes240416_lumykras_865-2023",
  "created_date": "2024",
  "country": "SE",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "Date Our designation",
      "text": "Amgen AB",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "DECISIONS",
      "text": "AIP AIP (SEK) AUP (SEK), 2024. 2024.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Other special conditions",
      "text": "product. product.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Phone Phone number",
      "text": "420 420 50",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "BACKGROUND",
      "text": "Lumycras Lumycras (sotorasib) cancer cancer (_MEDTERM1___) soasib soasib (CodeBreaK CodeBreaK 100) and docetaxel (study study SELECT-1) comparison comparison (MAIC). survival survival (LV Decision) rate rate (ITTERM3.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "THE THE DECISION",
      "text": "Agency Agency (TLV) following following reasons: • company company (dnr 1254/2024), 200 200 (AUP) June June • 200 200 (ADP) docetaxel. docetaxel. • 4800 4800 (A UP) cancer cancer (_MEDTERM1_) care. care. • Act. Act.",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Lumyclas medicinal product",
      "text": "the the patient'cancer cancer (_MEDTERM9___) state. state. Sotorasibe'mouth mouth (peroral). assessed assessed (dnr 141/2022) advanced advanced non–carcinoma carcinoma (TEM1_). cancer cancer (_MEDTERM9___) assessment assessment (dnr 141/2022) with with docetaxel) investigations investigations (dnr 141/2022) COD. COD. (the the cross-decision decision (dnr 141/2022) of of TLV'reduction reduction (dnr 1254/2023) the the decision: Berglunde. Berglunde.",
      "start_page": 3,
      "end_page": 8
    },
    {
      "heading": "HOW TO APPROVE",
      "text": "court. court.",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "Legal context",
      "text": "Act Act (2002:160) etc. etc. (hereinafter ‘the Preferential Act'), Act Act (2017:30), Act Act (2015:315), 3, 3, § that that TLV'decided. decided.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heading heading Phone Phone number",
      "text": "Row 1:\nName",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Heading Heading  Invented name Lumykras",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\npatient population.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Heading Heading  Invented name Lumykras",
      "text": "Row 1:\nlimit limit (RowRow 2:\ncancer cancer (_MEDTERM1__) RowRow 3:\nsystemic systemic treatment), assessment assessment (dnr 141/2022) RowRow 4:\nRowRow 5:\nassessment.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Heading Heading  Invented name Lumykras (from previous page)",
      "text": "Row 1:\npopulation population (RowRow 2:\nlung cancer (NSCLC) RowRow 3:\nRowRow 4:\nwith with docetaxel), RowRow 6:\noptions. options.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Heading Heading  Invented name Lumykras (from previous page)",
      "text": "Row 1:\nRowRow 2:\ndownwards. downwards.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Heading Heading  Invented name Lumykras (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nuncertainties. uncertainties.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Heading Heading  Invented name Lumykras (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\ncancer cancer (NSCLC) RowRow 4:\nRowRow 5:\ntreatment. treatment.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Heading Heading HUR MAN APPEALS",
      "text": "Row 1:\nRowRow 2:\ndecided decided (ref. no. 1254/2023) RowRow 3:\nJune June (2024).",
      "start_page": 8,
      "end_page": 8
    }
  ]
}